- Home
- WINT vs ONCO Comparison
WINT vs ONCO Comparison
Compare WINT & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- ONCO
- Stock Information
- Founded
- WINT 1992
- ONCO 2018
- Country
- WINT United States
- ONCO United States
- Employees
- WINT N/A
- ONCO N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- WINT Health Care
- ONCO Health Care
- Exchange
- WINT Nasdaq
- ONCO Nasdaq
- Market Cap
- WINT 1.5M
- ONCO 1.8M
- IPO Year
- WINT 1995
- ONCO 2022
- Fundamental
- Price
- WINT $1.20
- ONCO $0.07
- Analyst Decision
- WINT Hold
- ONCO
- Analyst Count
- WINT 1
- ONCO 0
- Target Price
- WINT $350.00
- ONCO N/A
- AVG Volume (30 Days)
- WINT 7.7M
- ONCO 9.2M
- Earning Date
- WINT 04-15-2025
- ONCO 05-19-2025
- Dividend Yield
- WINT N/A
- ONCO N/A
- EPS Growth
- WINT N/A
- ONCO N/A
- EPS
- WINT N/A
- ONCO N/A
- Revenue
- WINT N/A
- ONCO $1,870,605.00
- Revenue This Year
- WINT N/A
- ONCO N/A
- Revenue Next Year
- WINT N/A
- ONCO N/A
- P/E Ratio
- WINT N/A
- ONCO N/A
- Revenue Growth
- WINT N/A
- ONCO N/A
- 52 Week Low
- WINT $1.10
- ONCO $0.07
- 52 Week High
- WINT $737.50
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- WINT 25.91
- ONCO 17.45
- Support Level
- WINT $1.64
- ONCO $0.07
- Resistance Level
- WINT $2.17
- ONCO $0.15
- Average True Range (ATR)
- WINT 0.34
- ONCO 0.02
- MACD
- WINT 0.20
- ONCO 0.01
- Stochastic Oscillator
- WINT 4.20
- ONCO 9.41
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.